COLA: SCIDS Update

Price:  $25 members, $35 non-members

Session recorded on June 22, 2018

Speaker:  Eyal Grunebaum, MD

Viewers can earn credit by completing the posttest questions.

This activity is designed to provide updated knowledge about the management of SCID, particularly in the era of newborn screening for SCID and introduction of new treatment options.

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commerical support for this activity.

Learning Objectives

After viewing the video recording, learners should be able to: 

  • Describe typical features of SCID.
  • Recognize the impact of newborn screening for SCID on management practices.

  • Discuss advances in management of SCID
Additional information
Disclosure: 

Disclosure Policy and Disclosures                                                                            

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner

Speaker, honorarium:  Thermofisher, Boehringer Ingelheim

The individuals listed below disclose the following financial relationships:

Paul Dowling, MD, Planner

Eyal Grunebaum, MD, Speaker

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
06/29/2018
Course expires: 
06/29/2019
Cost:
$35.00
Rating: 
0

Speaker:  Eyal Grunebaum, MD

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commerical support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
06/29/2018
Course expires: 
06/29/2019

Price

Cost:
$35.00
Please login or create an account to take this course.